Effectiveness of epigallocatechin gallate nanoparticles on the in-vivo treatment of Alzheimer’s disease in a rat/mouse model: a systematic review
Document Type
Article
Publication Date
2024
Abstract
Background
Alzheimer’s disease (AD) is a neurological disease that causes memory loss over time. Current therapies are limited and frequently inadequate. Epigallocatechin gallate (EGCG), has antioxidant, anti-inflammatory, antifibrosis, anti-remodeling and tissue-protective qualities that may be effective in treatment of different diseases, including AD. Because of nanoparticles’ high surface area, they can enhance solubility, stability, pharmacokinetics and biodistribution, and diminish toxicities. Besides, lipid nanoparticles have a high binding affinity that can enhance the rate of drug transport across BBB. So, EGCG nanoparticles represent a promising treatment for AD.
Objectives
This systematic review sought to assess the efficacy of EGCG nanoparticles against AD in rat/mouse models.
Recommended Citation
Khalifa, Maha; Abdel-Sattar, Somaia; Amin, Omnya; Kohaf, Neveen; Zaky, Heba; Abd El‑Fattah, Marwa; Mohammed, Kamilia; Badawy, Noha; Mansoor, Ihab; and Eassa, Heba, "Effectiveness of epigallocatechin gallate nanoparticles on the in-vivo treatment of Alzheimer’s disease in a rat/mouse model: a systematic review" (2024). Pharmacy. 793.
https://buescholar.bue.edu.eg/pharmacy/793